Lifestyle

Ensol Bio Sets Its Sights on a "One-Shot" KOSDAQ Technology Evaluation in the First Half of Next Year… "P2K, H1K, E1K" Trio Takes Center Stage

Korea Exchange Successfully Concludes Second-Half IR Event on the 18th… Shinhan Investment Securities Replaced as Lead Underwriter 'Senior Executive Summit' with SpineBioPharma to Be Held in New York Early Next Month E1Corporation Confirms Phase 3 Trials at 20 University Hospitals; Obesity Drug H1K Proven to 'Prevent Weight Rebound'

YU JIN-HEE
2026-11-18 17:10:02
[Edaily Reporter YU JIN-HEE ] Ensol Biosciences, an innovative new drug developer listed on KONEX, has officially announced a “one-shot” strategy to pass the technology evaluation—a key hurdle for a technology-based special listing on KOSDAQ in the first half of next year—on the first attempt. Having completely resolved its financial uncertainties, the company is making a bold move to secure full recognition of its corporate value by highlighting tangible results from its core pipeline, including “P2K” for degenerative disc disease, “E1K” for knee osteoarthritis, and “H1K,” an oral obesity treatment.

On the 18th, Ensol Bio successfully concluded its “2026 Second-Half Investor Relations (IR) Briefing” held at the Korea Exchange in Yeouido, Seoul, and unveiled its roadmap for relisting on KOSDAQ along with global commercialization strategies for its key new drug pipelines.

(Photo: Ensol Biosciences)


At this IR event, Ensol Bio announced the progress made on the “three key tasks” necessary to complete its transfer listing to KOSDAQ. First, the company addressed financial risks, a chronic weakness of biotech ventures. The company significantly strengthened its capital soundness through a series of measures, including a large-scale common stock investment by CEO Hyung In-woo, the company’s largest shareholder; a common stock investment by Capstone Partners Co., Ltd.; and the conversion of convertible bonds (CBs) into common stock. Additionally, the company secured stable R&D liquidity by receiving the full 4 billion won advance payment under the domestic exclusive distribution agreement for its osteoarthritis treatment E1K, recently signed with LEADERS COSMETICS CO.,LTD.(016100).

Preparations for the IPO have also been finalized. Shinhan Investment Securities was reappointed as the lead underwriter, and an intensive due diligence process was conducted. Furthermore, the company has completed the revision of its technology business plan, centering on its core proprietary technology, the “Bio-mimetic SSR™ Peptide Platform.”

Considering the conservative investment sentiment in the biotech sector, the company has decided not to rush the IPO. Instead, it will focus on the “three key momentum drivers” that converge in 2027: △progress in P2K’s discussions with the U.S. Food and Drug Administration (FDA) regarding accelerated approval; △the entry into due diligence for the technology transfer (L/O) of the oral weight-loss drug H1K to a global big pharma company; △the demonstration of cancer cell killing efficacy in animal models for the anti-cancer peptide radiopharmaceutical (D1K-PRC)—the company has identified the first and second quarters of 2027, when these “three key momentum drivers” converge, as the optimal timing to enter the technology evaluation phase.

The timeline for the global commercialization of the company’s flagship pipeline is also moving rapidly. P2K, currently under joint development with U.S. partner Spine Biopharma, will host an “Executive Summit” on December 1–2 at Spine Biopharma’s headquarters in New York, with top executives from both companies in attendance.

At this event, executives from both companies plan to engage in in-depth discussions on: △ the FDA’s Accelerated Approval pathway and timeline; △ governance for sharing clinical data; and △ joint strategies for engaging the U.S. capital markets and pursuing a NASDAQ listing. Based on these discussions, the company plans to accelerate the process of obtaining Accelerated Approval following consultations on the FDA regulatory pathway in 2027.

E1K, currently undergoing a Phase 3 clinical trial in Korea, has successfully completed dosing for the safety cohort of six patients and is progressing smoothly. NGeneBio Co., Ltd. has secured the participation of 20 major university hospitals nationwide, including Samsung Seoul Hospital, in the main clinical trial and will begin administering the drug to 358 participants in April of next year. While striving to prove that H1K is a disease-modifying osteoarthritis drug (DMOAD) that regenerates cartilage—going beyond mere pain relief—the company is simultaneously conducting technology transfer negotiations in regions such as China, India, and the U.S.

The latest preclinical results for H1K, which is regarded as a next-generation growth engine, have drawn significant market attention. H1K features a “pH-selective dual-target regulation” mechanism that activates “IGF-1R,” which regulates metabolic signaling, in the acidic environment of the gastrointestinal tract (pH 2–5), while inhibiting “CD28,” an inflammatory mediator, in the neutral environment of the liver (around pH 7.4), thereby simultaneously improving liver inflammation and metabolic abnormalities.

In particular, preclinical efficacy studies demonstrated that H1K significantly suppressed the weight rebound (yo-yo effect) typically observed after discontinuing co-administration with global glucagon-like peptide-1 (GLP-1) class obesity treatments. Emerging as a game-changer capable of resolving the yo-yo effect—widely regarded as the greatest limitation of existing obesity drugs—EnsolBio has secured the data package required by global big pharma and has abruptly resumed discussions on technology transfer.

Its follow-up pipeline and new business ventures are also gaining momentum. “M1K,” a treatment for Alzheimer’s disease, has demonstrated efficacy in restoring normal cognitive function in animal models of the disease, and the company is preparing to submit an Investigational New Drug (IND) application for a Phase 1 clinical trial in the first half of next year. In addition, combination anticancer drugs for triple-negative breast cancer, non-small cell lung cancer, and colorectal cancer (C1K, C2K, C3K), the peptide radiopharmaceutical “D1K-PRC” being jointly developed with Saehan Industries, and the supply business for K-Beauty cosmetic ingredients (M1K-PS01, A1K) are all progressing smoothly.

These achievements are underpinned by the scientific credibility of the biomimetic Sinseonjo™ platform, which is based on the company’s proprietary drug discovery system (ESAIDD). Research findings on E1Corporation and C1K were published in “Osteoarthritis and Cartilage,” the leading journal in the field of osteoarthritis(IF 9.2) and the leading journal on biopolymers, *International Journal of Biological Macromolecules* (IF 8.7), respectively, while the M1K paper is currently undergoing peer review in a world-renowned interdisciplinary science journal (IF 14.1).

Kim Hae-jin, CEO of Ensol Bio, emphasized, “We are resolving financial uncertainties and accumulating tangible results in the clinical development and global partnering of our core pipeline,” adding, “We will maximize shareholder value by entering the KOSDAQ technology evaluation process at the optimal time, in conjunction with the achievement of key R&D and commercialization milestones in the first half of next year.”

Economy

Corporation

IT·Science

Economy

HyundaiMotor Group Completes Restructuring Focused on Commercial Robots… Atlas Welcomes Its First Semiconductor Customer

Boston Dynamics’ humanoid robot Atlas (right) and quadruped robot Spot (left). (Photo courtesy of HyundaiMotor Group) HyundaiMotor Group has completed a business restructuring centered on commerci…
2026-11-18 17:17:41

Corporation

Ensol Bio Sets Its Sights on a "One-Shot" KOSDAQ Technology Evaluation in the First Half of Next Year… "P2K, H1K, E1K" Trio Takes Center Stage

Ensol Biosciences, an innovative new drug developer listed on KONEX, has officially announced a “one-shot” strategy to pass the technology evaluation—a key hurdle for a technology-based special listin…
2026-11-18 17:10:02

IT·Science

NHN Officially Launches New Puzzle Game ‘My Favorite Child: Puzzle Star’ in Over 170 Countries Worldwide

NHN(181710)announced on the 18th that it has officially launched the match-3 puzzle game “My Favorite Child: Puzzle Star” in over 170 countries worldwide. (Photo courtesy of NHN) “My Favorite Ch…
2026-11-18 14:57:27